bromocriptine has been researched along with Disease Exacerbation in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, C; Guan, S; Kang, J; Li, Y; Liu, H; Sun, B; Wang, W; Zhang, J | 1 |
| Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H | 1 |
| Akinduro, OO; Bernet, V; Chaichana, KL; De Biase, G; Donaldson, A; Izzo, A; Lu, VM; Meyer, FB; Olomu, O; Quinones-Hinojosa, A; Van Gompel, JJ; Vilanilam, G | 1 |
| Blonde, L; Chamarthi, B; Cincotta, AH; Ezrokhi, M; Gaziano, JM; Rutty, D; Scranton, RE; Vinik, A | 1 |
| Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M | 1 |
| Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X | 1 |
| Gillman, K | 1 |
| Halliday, GM; Hely, MA; Loy, C; Morris, JG; Reid, WG | 1 |
| Hadano, S; Ikeda, JE; Kanno, T; Tanaka, K; Yanagisawa, Y; Yasutake, K; Yoshii, F | 1 |
| Kondo, T | 1 |
| Hely, MA; Morris, JG; Reid, WG; Trafficante, R | 1 |
| Hoffmann, A; Klotz, P; Kraus, PH; Lewe, J; Przuntek, H | 1 |
| Bonuccelli, U; Ceravolo, R; Del Dotto, P; Gambaccini, G; Logi, C; Lucetti, C; Murri, L; Rossi, G | 1 |
| Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
| Turnbull, GI | 1 |
| Falk, M; Künig, G; Neubauer, M; Ransmayr, G; Wagner, M | 1 |
| Akiguchi, I; Fukuyama, H; Imai, T; Kawamura, J; Kimura, J | 1 |
| Goto, I; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F | 1 |
| Alatli, C; Aydin, Y; Can, SM; Gŭlkilik, A; Tŭrkmenoglu, O; Ziyal, I | 1 |
| Chuda, M; Hayabara, T; Ihara, Y; Kuroda, S | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
2 review(s) available for bromocriptine and Disease Exacerbation
| Article | Year |
|---|---|
Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.
Topics: Adult; Bromocriptine; Carcinoma; Craniotomy; Disease Progression; Female; Hormone Antagonists; Humans; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Reoperation; Spinal Cord Neoplasms | 2021 |
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2002 |
6 trial(s) available for bromocriptine and Disease Exacerbation
| Article | Year |
|---|---|
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.
Topics: Adult; Aged; Aging; Antiparkinson Agents; Bromocriptine; Disease Progression; Female; Gait; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Psychomotor Performance; Tremor | 1995 |
Bromocriptine therapy in early-stage Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Disease Progression; Drug Therapy, Combination; Evaluation Studies as Topic; Follow-Up Studies; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Time Factors; Treatment Outcome | 1996 |
Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Selegiline; Severity of Illness Index; Treatment Outcome | 1998 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
14 other study(ies) available for bromocriptine and Disease Exacerbation
| Article | Year |
|---|---|
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult | 2020 |
Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Topics: Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Factors; Treatment Failure; Tumor Burden | 2019 |
Prolactinomas: evolution after menopause.
Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2016 |
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome | 2016 |
In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine".
Topics: Antipsychotic Agents; Benzodiazepines; Bromocriptine; Chlorpromazine; Disease Progression; Dopamine Agonists; Drug Overdose; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Serotonin Receptor Agonists; Treatment Outcome | 2009 |
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Cognition; Cohort Studies; Dementia; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; New South Wales; Parkinson Disease; Survival Analysis | 2011 |
Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anterior Horn Cells; Bromocriptine; Disease Models, Animal; Disease Progression; Dopamine Agonists; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neuroglia; Neuronal Apoptosis-Inhibitory Protein; Receptors, Dopamine D2; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1; Treatment Outcome; Up-Regulation | 2011 |
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Dementia; Disease Progression; Dose-Response Relationship, Drug; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Mortality; Movement Disorders; Multicenter Studies as Topic; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Time Factors | 2005 |
Analysis of the course of Parkinson's disease under dopaminergic therapy: performance of "fast tapping" is not a suitable parameter.
Topics: Bromocriptine; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Bromocriptine; Disability Evaluation; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pergolide; Prognosis; Survival Analysis | 2006 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Changes in gait and symptoms after bilateral pallidotomy: a client with Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Disease Progression; Female; Gait; Globus Pallidus; Humans; Levodopa; Middle Aged; Pallidotomy; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Rapid enlargement and recurrence of a preexisting intrasellar craniopharyngioma during the course of two pregnancies. Case report.
Topics: Adult; Bromocriptine; Craniopharyngioma; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Hormone Antagonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma; Sphenoid Bone | 1999 |
Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Erythrocytes; Humans; Hydroxyl Radical; Levodopa; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pergolide; Severity of Illness Index; Statistics as Topic; Superoxide Dismutase; Time Factors | 1999 |